Available levels of proteins can cause competition between binding partners, which then can in turn shunt pathways to be activated, inhibited or perhaps balance out.
Membrane lipids can achieve these different outcomes through different interactions with their binding partners, which are mostly proteins and/or other lipids.
Finally, also using this database, users can carry out a comprehensive search on RGS4 including potential inhibitory sites and other binding partners, which might be needed for further studies.
This is the structure of the ecdysone receptor in partner with its drosophila binding partner, which is ultraspiracle.
IDPRs provide excessively large, malleable binding surfaces, which can associate with promiscuous partners resulting in distinct, even opposite functions.
Protein protein interface structures can also indicate which binding partners can interact simultaneously and which are competitive, and can help forecasting potentially harmful drug side effects.
Formation of such binding intermediates results in the structural changes in a partner molecule leading to the exposure of its "hidden" binding site, which can be accessed by an IDP due to its structural flexibility.
Here we examine the non-specific component of protein-protein interactions, which refers to those physicochemical properties of the binding partners that are independent of the exact details of their binding sites, but which can affect their localization or diffusional search for one another.
The first step in the recognition of LPS involves its binding to LPS-binding protein (LBP), which can be found in the blood or extracellular fluid.
We also examined the expression of the small-heterodimer partner (SHP), which can heterodimerise with activated receptors and prevent transactivation of DNA as it lacks a DNA binding domain [27].
